Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities

Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant in Garnet Valley, Pennsylvania. The facility, spanning 45,000 square feet and representing a $15 million investment, is set to enhance the company’s capabilities in drug formulation and clinical trial manufacturing.

The new Garnet Valley plant will focus on developing small molecule oral drug products and supporting development programs from preclinical stages through clinical proof-of-concept. This expansion aligns with Quotient Sciences’ strategy to address growing customer demand for early-phase formulation and clinical trial services. The company’s existing Chelsea Parkway facility will continue to handle scale-up to late-phase manufacturing and commercial product supply.

Mark Egerton, CEO of Quotient Sciences, emphasized the facility’s strategic importance: “Our new facility was built in response to increasing customer demand for our early-phase formulation development and clinical trial manufacturing services. The site was specifically designed to optimize our ability to work with highly potent and poorly soluble molecules that dominate the industry pipeline. The facility also increases our capacity to provide integrated Translational Pharmaceutics programs in the U.S., which deliver substantial benefits to customers including cost savings and reduced timelines to achieve proof-of-concept.”

Key Features of the Garnet Valley Facility

The new plant is equipped to handle both potent and non-potent products with six Good Manufacturing Practice (GMP) suites. It supports various dosage forms, including liquids, solids, immediate-release, and modified-release products. Quotient Sciences also offers solubilization technologies such as spray-dried dispersions, micronized, and lipidic formulations.

The facility integrates Translational Pharmaceutics programs, which merge real-time adaptive manufacturing with clinical research. This approach allows for rapid delivery of drug products to clinical trials and pharmacology units globally, with customizable batch sizes and flexible dose adjustments.

Looking Ahead

Quotient Sciences plans to announce further expansions to its formulation and manufacturing operations in the coming months. The company aims to continue enhancing its service offerings to biotech and pharmaceutical clients, focusing on innovative and efficient drug development solutions.